Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Japan's Takeda to buy...

    Japan's Takeda to buy US cancer drug maker Ariad in $5.2 billion deal

    Written by supriya Published On 2017-01-13T14:18:09+05:30  |  Updated On 13 Jan 2017 2:18 PM IST
    Japans Takeda to buy US cancer drug maker Ariad in $5.2 billion deal

    Japan's Takeda Pharmaceutical Co Ltd said it would buy cancer drug maker Ariad Pharmaceuticals Inc in a deal valued at $5.20 billion, to beef up its oncology pipeline.


    Takeda which in September revealed it was scouting for multi-billion dollar acquisitions to reduce its dependence on domestic sales agreed to pay $24 for each Ariad share, a premium of about 75 percent to its Friday close.


    Ariad stock was up 73 percent at $23.77 in morning trading on Monday. In 2016, its shares had nearly doubled.


    Takeda's top-selling blood cancer drug Velcade is expected to face generic competition this year and other key products go off patent from 2020.


    Cancer drugs are appealing to large drugmakers, with high prices being paid for promising assets. San Francisco-based Medivation was bought by Pfizer Inc for $14 billion in August.


    Given the scarcity of commercial-stage oncology assets and significant potential synergies, other Ariad bidders could emerge, SunTrust Robinson analysts said.


    In November, Reuters reported that Takeda's negotiations to acquire Valeant Pharmaceuticals International Inc's Salix stomach-drug business had stalled, citing sources.


    With the Ariad deal, the Japanese drug giant gains access to the leukemia drug, Iclusig, which is expected to generate sales of $170 million-$180 million in 2016.


    Ariad came under fire in October for price increases of Iclusig.


    A U.S. Food and Drug Administration decision on its lung cancer treatment, brigatinib, which is being touted as a potential blockbuster, is expected by April.


    Sarissa Capital Management LP, a hedge fund run by investor Carl Icahn's former healthcare lieutenant, had announced a stake in Ariad in 2013.


    Sarissa will tender its shares to Takeda, if the deal goes through.


    Ariad suspended Iclusig sales in 2013 after data showed it was associated with serious complications, but resumed marketing after the FDA sanctioned its use in a narrower patient population.


    The equity value of the deal, which is expected to add to Takeda's earnings in 2018, is $4.66 billion, according to Reuters calculations. Takeda plans to fund the transaction by taking on $4 billion in new debt.


    Evercore Partners is Takeda's financial adviser, while Cleary Gottlieb Steen & Hamilton LLP are providing legal counsel. Ariad's financial advisers include J.P. Morgan, Goldman Sachs and Lazard, while Paul, Weiss, Rifkind, Wharton & Garrison LLP is its legal counsel.


    Takeda's last major deal was in 2011 when it paid nearly $14 billion for Swiss drugmaker Nycomed.

    Ariad Pharmaceuticalscancercancer drugJP MorganPfizerSunTrust RobinsonTakeda
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya
    supriya
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok